Assessing Target Engagement for Terazosin in Parkinson's Disease (TZPD2)
| Registry | NCT07464028, acronym TAME-PD: |
|---|
| Status | Suspended - Study not funded |
|---|
| Phase | Phase 2 |
|---|
| Study type | Interventional; randomized, parallel, masking: triple, basic science |
|---|
| Enrollment | 120 (Estimated) |
|---|
| Sponsor | Ergun Y. Uc (Other) |
|---|
| Conditions | Parkinson's Disease (PD) |
|---|
| Interventions | Terazosin 5 MG, Placebo (Drug) |
|---|
| Dates | start 2028-07-01 (estimated), primary completion 2030-07-01 (estimated), completion 2031-07-01 (estimated), first posted 2026-03-11, last updated 2026-10-09 |
|---|
| Locations | 1 site in United States |
|---|
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Parkinson's Disease (PD) All trials of Terazosin 5 MG All trials of Placebo
-Summary
This study investigates if Terazosin can improve metabolism in PD.
Expand all sections · Collapse all
+Arms and interventions
| Arm | Type | Interventions | Description |
|---|
| Active arm | Experimental | Drug: Terazosin 5 MG | Terazosin 5 mg |
| Placebo | Placebo comparator | Drug: Placebo | Placebo |
- Terazosin 5 MG (Drug): This drug increases glycolysis in Parkinson's disease.
- Placebo (Drug): Placebo control for Terazosin
+Outcome measures
Primary outcomes
- ATP [at 1.5 year]: Changes in whole-blood ATP relative to baseline at 6 weeks and 1.5 years
+Eligibility
Sex: All, ages: 50 Years to 80 Years
Parkinson's disease
+Locations (1)
| Facility | City | Country | Status |
|---|
| University of Iowa | Iowa City, Iowa | United States | |
+Publications
- Schultz JL, Gander PE, Workman CD, Boles Ponto LL, Cross S, Nance CS, Groth CL, Taylor EB, Ernst SE, Xu J, Uc EY, Magnotta VA, Welsh MJ, Narayanan NS. A dose-finding study shows terazosin enhanced energy metabolism in neurologically healthy adults. J Parkinsons Dis. 2025 Nov;15(7):1253-1263. doi: 10.1177/1877718X251356503. Epub 2025 Aug 10. PMID 40785306
- Cai R, Zhang Y, Simmering JE, Schultz JL, Li Y, Fernandez-Carasa I, Consiglio A, Raya A, Polgreen PM, Narayanan NS, Yuan Y, Chen Z, Su W, Han Y, Zhao C, Gao L, Ji X, Welsh MJ, Liu L. Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. J Clin Invest. 2019 Oct 1;129(10):4539-4549. doi: 10.1172/JCI129987. PMID 31524631
- Simmering JE, Welsh MJ, Liu L, Narayanan NS, Pottegard A. Association of Glycolysis-Enhancing alpha-1 Blockers With Risk of Developing Parkinson Disease. JAMA Neurol. 2021 Apr 1;78(4):407-413. doi: 10.1001/jamaneurol.2020.5157. PMID 33523098
- Schultz JL, Brinker AN, Xu J, Ernst SE, Tayyari F, Rauckhorst AJ, Liu L, Uc EY, Taylor EB, Simmering JE, Magnotta VA, Welsh MJ, Narayanan NS. A pilot to assess target engagement of terazosin in Parkinson's disease. Parkinsonism Relat Disord. 2022 Jan;94:79-83. doi: 10.1016/j.parkreldis.2021.11.022. Epub 2021 Nov 27. PMID 34894470
- Simmering JE, Welsh MJ, Schultz J, Narayanan NS. Use of Glycolysis-Enhancing Drugs and Risk of Parkinson's Disease. Mov Disord. 2022 Nov;37(11):2210-2216. doi: 10.1002/mds.29184. Epub 2022 Aug 22. PMID 36054705
- Weber MA, Sivakumar K, Tabakovic EE, Oya M, Aldridge GM, Zhang Q, Simmering JE, Narayanan NS. Glycolysis-enhancing alpha1-adrenergic antagonists modify cognitive symptoms related to Parkinson's disease. NPJ Parkinsons Dis. 2023 Mar 2;9(1):32. doi: 10.1038/s41531-023-00477-1. PMID 36864060
- Hart A, Aldridge G, Zhang Q, Narayanan NS, Simmering JE. Association of Terazosin, Doxazosin, or Alfuzosin Use and Risk of Dementia With Lewy Bodies in Men. Neurology. 2024 Jul 23;103(2):e209570. doi: 10.1212/WNL.0000000000209570. Epub 2024 Jun 19. PMID 38896813